Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma

被引：82

作者：

Yin, Shucheng ^{[1
,2
]}

Girnita, Ada ^{[1
]}

Stromberg, Thomas ^{[1
]}

Khan, Zahidul ^{[3
]}

Andersson, Sandra ^{[1
]}

Zheng, Huiyuan ^{[1
]}

Ericsson, Christer ^{[1
]}

Axelson, Magnus ^{[1
,4
]}

Nister, Monica

Larsson, Olle ^{[1
]}

Ekstrom, Tomas J. ^{[3
]}

Girnita, Leonard ^{[1
]}

机构：

[1] Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, S-17176 Stockholm, Sweden

[2] Wuhan Univ, Zhongnan Hosp, Dept Otolaryngol Head & Neck Surg, Wuhan 430071, Peoples R China

[3] Karolinska Inst, Dept Clin Neurosci, S-17176 Stockholm, Sweden

[4] Karolinska Inst, Karolinska Univ Hosp, S-17176 Stockholm, Sweden

来源：

NEURO-ONCOLOGY | 2010年 / 12卷 / 01期

基金：

瑞典研究理事会;

关键词：

glioblastoma; glioma; IGF-1; receptor; picropodophyllin; HUMAN-MALIGNANT GLIOMA; IGF-1; RECEPTOR; MULTIPLE-MYELOMA; BREAST-CANCER; MOUSE MODEL; CELLS; INHIBITION; REGRESSION; PROTEIN; ACTIVATION;

D O I：

10.1093/neuonc/nop008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Glioblastoma (GB) is the most common malignant brain tumor in adults. It has limited treatment opportunities and is almost exclusively fatal. Owing to the central role the insulin-like growth factor-1 receptor (IGF-1R) plays in malignant cells, it has been suggested as a target for anticancer therapy including GB. The cyclolignan picropodophyllin (PPP) inhibits IGF-1R without affecting the highly homologous insulin receptor. Here, we show that PPP inhibits growth of human GB cell lines along with reduced phosphorylation of IGF-1R and AKT. In vivo, PPP-treatment causes dramatic tumor regression not only in subcutaneous xenografts but also in intracerebral xenografts, indicating passage of PPP across the blood-brain barrier.

引用

页码：19 / 27

页数：9

共 32 条

[1]

Targeting the IGF-1 receptor: from rags to riches [J].